The association between subclinical hypothyroidism and TPOAb positivity with infertility in a population-based study: Tehran thyroid study (TTS)

Batul Birjandi¹, Fahimeh Ramezani Tehrani², Atieh Amouzegar¹*, Maryam Tohidi³, Razieh Bidhendi Yarandi²,⁴ and Feriedoun Azizi¹

Abstract

Background: Thyroid autoimmunity (TAI) is the most prevalent autoimmune condition in women of fertile age. There are increasing data regarding the association of thyroid dysfunction and thyroid autoimmunity with adverse pregnancy outcomes but there is no consensus regarding infertility and TPOAb positivity; thus we aimed to evaluate the association between thyroid TPOAb positivity and infertility in females and males in a population-based study (TTS).

Methods: Cross-sectional study of 3197 female and male participants in Tehran Thyroid Study (TTS) at the framework of the Tehran Lipid and Glucose Study (TLGS). Data included biochemical measurements and a self-administered questionnaire.

Results: A total of 12,823 cases in phase 4, 3719 cases (2108 female and 1611 male) were analyzed. The mean TSH of the infertile female and male was $2.52 \pm 2.68 \mu U/ml$ and $3.24 \pm 10.26 \mu U/ml$ respectively. The TPO median (IQR) of women with and without a history of infertility were $6.05 (3.30–13.96)$ and $6.04 (3.17–11.15); (P = 0.613)$, they were $5.08 (3.20–125.68)$ and $5.31 (3.93–125.68); (P = 0.490)$ in male participants, respectively. Results of crude and adjusted logistic regression analysis of the development of infertility by thyroid function and TPOAb, except for fT4 in male subjects, depicted no association between infertility and other variables in both crude and adjusted models.

Conclusion: Based on the result, thyroid autoimmunity was not associated with infertility in both females and males.

Keywords: Thyroid TPO positivity, Infertility
Background
Thyroid autoimmunity (TAI) is defined presence of cell and humoral immune response against thyroid antigens with subsequent infiltration of T cells and B cells, autoantibodies production and, finally, the development of different clinical manifestations [1]. TAI is the most prevalent autoimmune condition in women of fertile age [2]. The mechanisms describe including thyroid-stimulating hormone (TSH) dependent mechanism or independent of TSH in a variety of mechanisms such as immunoregulatory, vitamin D deficiency and cross-reactivity of thyroid autoantibodies to extra thyroid sites [3]. There is increasing data regarding the association of thyroid dysfunction and thyroid autoimmunity with adverse pregnancy outcomes such as recurrent miscarriage and recurrent embryo implantation failure [4–6].

Although the uterus and ovary in females and gonadal steroids, testosterone level, spermatogenic function in males can be targeted by thyroid antibodies, there is no consensus regarding the exact mechanism of infertility influenced by thyroid autoimmunity [7, 8]. The results of available studies on the association between TAI and infertility are rare and controversial especially in males and are limited by study designs, small sample size, heterogeneity in participants and lack of complete sociodemographic data [9–12]. Additionally, there are few population-based studies to reveal this association [13].

In the Iranian population, the prevalence of primary infertility is 17.3% in couples indicates that is a common problem in our society [14]; thus we aimed to evaluate the association between thyroid peroxidase antibody (TPOAb) positivity and infertility in a population-based study in both male and female.

Methods
Participants
Details of the present study design have been reported elsewhere [15]. In short, this is a cross-sectional study within the framework of the Tehran Thyroid Study (TTS), a prospective population-based cohort study was conducted on residents of Tehran’s 13th district between March 1997 and December 2004. A total of 5769 participants aged ≥20 years, were selected using multistage cluster random sampling. The TTS is being conducted within the framework of Tehran Lipid and Glucose Study (TLGS), an ongoing community base study with 3-year interval follow-ups, for identification and prevention of non-communicable disease.

For the purpose of the present study, we excluded all those unmarried women, those with unwilling pregnancy and duration of marriage below 1 year. A specific questionnaire including age, education, reproductive history, contraceptive behaviors, smoking, menstrual pattern, fertility history (including age of marriage, number of parity, number of birth, time to pregnancy, number of abortion) and seeking medication for infertility was collected through face to face interviews by a trained midwife. For those ones with uncertain data in terms of infertility, medical documents had been evaluated (supplementary data). The content validity of this questionnaire was assessed by 15 gynecologists and reproductive health experts. The reliability of the instrument was determined using test-retest to determine the level of agreement between responses in a 10 days-interval (r = 0.91). Internal consistency was measured using Cronbach’s alpha correlation coefficient (α = 0.79) details have been published elsewhere [16].

Male infertility was identified based on evaluating the medical documents of the infertile couples.

Out of 12,823 subjects participated in 3rd follow-up of TLGS, we excluded all those never married women or men (n = 835), those couples who had never willingness for having a baby (n = 62), those with uncertain data regarding reproductive and fertility history (n = 3969) and those with missing values of TSH, free T4 (fT4), TPOAb (n = 715), those overt Hypothyroidism/ Hyperthyroidism(n = 11). Finally, there were 3629 participants including 2108 females (382 with infertility) and 1611 males (88 with infertility) who met our eligibility criteria for the purpose of the present study. A total of 470 infertile (88 males and 382 females) and 3249 fertile (1523 males and 1726 females). The study flowchart is presented in Fig. 1.

Definition terms
- infertility was defined as the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse whether or not having a child due to male or female factors [17].
- Number of birth: the number of complete expulsion or extraction from a woman of a fetus after 22 completed weeks of gestational age, irrespective of whether it is a live birth or stillbirth [17].
- Number of abortion was defined the number of pregnancy loss without outside intervention before 20 weeks gestation [18].
- Time to pregnancy was defined the time between the decision to pregnancy and become pregnant) measured in months or in numbers of menstrual cycles [17].
- Thyroid status has been subcategorized as follows; Euthyroidism was defined as normal TSH within the range of 0.32–5.06 mU/L and fT4 of 0.91–1.55 ng/dL. Subclinical hypothyroidism was defined as TSH levels > 5.06 and < 10 mU/L and fT4 of 0.91–1.55 ng/dL and not using LT4. Subclinical
hyperthyroidism was defined as TSH levels < 0.32 mIU/L and fT4 of 0.91–1.55 ng/dL. TPOAb positivity was defined as TPOAb> 35 IU/mL for females and TPOAb> 32 IU/mL for males [19].

**Laboratory measurements**

All laboratory assays were performed on serum samples stored at −70 °C. TSH and fT4 were measured by the electrochemiluminescence immunoassay (ECLIA), using Roche Diagnostics kits & Roche/Hitachi Cobas e-411 analyzer (GmbH, Mannheim, Germany). For monitoring accuracy of assays, lyophilized quality control material (Lyphochek Immunoassay Plus Control; Bio-Rad Laboratories, Irvine, CA, USA) was used; intra- and inter-assay coefficients of variation (CV) were 1.3 and 3.7% for fT4 and 1.5 and 4.5% for TSH measurements, respectively. TPOAb was determined by immunoenzymometric assay (IEMA) using commercial kits (Monobind, Costa Mesa, CA, USA) and the Sunrise reader (Tecan Co., Salzburg, Austria); intra- and inter-assay CVs were 3.9 and 4.7%, respectively. All immunoassay tests were performed in the same laboratory by skilled laboratory technicians.

The study was approved by the Regional Ethics Committee of Shahid Beheshti, Iran (Reg.number IR.SBMU.MSP.REC.1399.282) and confirmed to the principle of the Declaration of Helsinki.

The flowchart of participants shows in Fig. 1.

**Statistical analysis**

Descriptive statistics were presented in mean(±SD) or median (IQR) for normal and non-normal variables and n(%) for categorical data. For two groups and three groups comparisons, t-test or mann-whitney U tests and ANOVA or Kruskal Wallis tests for normal and non-normal continuous variables was applied. Crude and adjusted Logistic regression were used to estimate odds ratio (95% CI) of infertility. Crude and adjusted linear regression models were used to model the time to pregnancy. Statistical analysis was done using STATA software (version 10; STATA, INC, college station, TX, USA).
Results
Of all 2108 enrolled women, 382 women had a history of female infertility. In male participants, there were 88 men with a history of infertility out of 1611 ones. Table 1 presents the characteristics of study participants according to fertility history. The mean age (±SD) of women with and without a history of infertility were 39y (±7) and 40y (±7) in the fertile group (P = 0.02), they were 59y(±14) and 54y(±11) in fertile and infertile male participants, respectively. The median(IQR) of TPO-Ab in women with and without a history of infertility were 6.04 (3.17–11.15) and 6.05 (3.30–13.96) IU/ml; (P = 0.613), they were 5.31 (3.93–125.68) and 5.08 (3.20–125.68) IU/ml; (P = 0.490) in male participants respectively.

Table 1 presents the Odds Ratio and 95% Confidence interval of TPOAb positivity and female infertility and abortion; it was 0.98 95%CI: (0.7–1.4); P = 0.721 for infertility and 1.04 95%CI: (0.8–1.4); P = 0.845, respectively.

The result of crude and adjusted logistic regression analysis of thyroid function tests and infertility (both male and female) is presented in Table 3. It has been shown that except for fT4 in male participants, there was no association between infertility and other thyroid function tests in both crude and adjusted models (Table 3; it has been shown that the odds ratio of male infertility was increased by 0.189 95% CI (0.056, 0.637), with each unit increase in fT4; the results remained statistically significant after multiple adjustment by Age, education, BMI, Smoking, Systolic&Diastolic BP, FBS (0.26595% CI (0.075, 0.940), P = 0.040. Linear regression analysis revealed no association between time to pregnancy, the number of abortions and parity with TSH, fT4 and TPOAb positivity in women (Table 4); moreover we found no association between infertility (both male and female) with TSH, fT4 and TPOAb positivity (Table 4).

Discussion
In the present study, we found that TPOAb positivity was not associated with infertility (male or female), abortion, time to pregnancy and parity. Our study revealed there was no association between infertility and other thyroid function tests with both male and female infertility, except fot fT4; there was a positive association

| Table 1 | baseline characteristic in participants if normal distribution mean if not median |
|---------|-----------------------------|
|          | Hx of Fertility | Hx of Infertility | * P value |
| **Female** | | | |
| Age (Y) | 40(±7) | 39(±7) | * 0.021 |
| TTP (mth) | 2.00 (1.00–4.00) | 15.00 (12.00–36.00) | * 0.000 |
| No of birth | 2.00 (2.00–3.00) | 2.00 (1.00–3.00) | * 0.001 |
| No of parity | 2.00 (2.00–3.00) | 2.00 (1.00–3.00) | * 0.001 |
| No of abortion | 0.00 (0.00–1.00) | 0.00 (0.00–1.00) | 0.452 |
| BMI (kg/m²) | 28.26 (25.33–31.25) | 28.44 (25.43–32.44) | 0.241 |
| SBP (mmHg) | 109.34(±12.76) | 109.45(±14.05) | 0.601 |
| DBP (mmHg) | 73.53(±9.88) | 73.87(±10.48) | 0.617 |
| FBS (mg/dl) | 87.00 (81.00–93.00) | 88.00 (82.00–94.00) | 0.193 |
| FT4(ng/dl) | 1.18 (1.08–1.30) | 1.18 (1.08–1.32) | 0.724 |
| TSH (mU/L) | 1.83 (1.07–3.06) | 2.04 (1.11–3.31) | 0.165 |
| TPOAb (IU/ml) | 6.05 (3.30–13.96) | 6.04 (3.17–11.15) | 0.613 |

**Male**

| Age(Y) | 54(±11) | 59(±14) | *0.003 |
| BMI (kg/m2) | 26.89 (24.49–34.21) | 25.69 (23.88–37.33) | 0.190 |
| SBP (mmHg) | 119.11 (±17.45) | 127.12 (±24.16) | * 0.000 |
| DBP (mmHg) | 78.21 (±10.73) | 80.48 (±12.86) | 0.155 |
| FBS (mg/dl) | 92.00 (86.00–141.00) | 94.00 (88.00–205.00) | * 0.011 |
| TPOAb (IU/ml) | 5.08 (3.20–125.68) | 5.31 (3.93–125.68) | 0.490 |
| FT4(ng/dl) | 1.30 (1.16–1.63) | 1.26 (1.11–1.57) | * 0.042 |
| TSH (mU/L) | 1.50 (0.87–6.17) | 1.79 (0.89–7.21) | 0.196 |

*Data are shown as mean ± SD and median, IQR, IQR interquartile range, Y year, TTP Time to pregnancy was defined just for participants with Hx of pregnancy (the time between the decision to pregnancy and become pregnant), mth month, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FBS fasting blood sugar, TSH thyrotropin, FT4 free thyroxine, TPO thyroid peroxidase antibody

*P-value obtained from t-student or Mann-Whitney U tests for normal or non-normal continuous variables, significant level was considered as p-value < 0.05
between serum concentration of Ft4 among male participants with infertility.

Thyroid antibodies may affect reproductive system with alteration in TSH/T4 levels directly but other mechanisms such as association with anti thyroglobulin, abnormal innate and humoral immunity, concurrent autoimmunity (i.e, endometriosis), vitamin D deficiency can ensue implantation failure in the absence of thyroid dysfunction [3].

Data on the association between thyroid autoimmunity and infertility is inconclusive and limited by limited number of comprehensive population based study [13, 20–22]. In a cross-sectional study on 11,565 European origin women, they found a negative association between TPOAb levels and parity; but not with the number of pregnancies and spontaneous abortion [13]. The difference in race and age distribution may partly explain different results.

In a case-control study in Iran by HABIB ZV et al. in 75 euthyroid women with unexplained infertility, serum anti-TPO antibodies were significantly higher in infertile euthyroid women comparing to healthy groups [20]. In another case-control study by Gupta J et al. in 50 infertile women, anti-thyroid antibodies were more prevalent in patients with infertility [21] and Manhas S et al. reported in 100 infertile female, Anti-TPO Ab was independently associated with infertility irrespective of thyroid hormones levels [22]. The positive findings of these case control studies may be due to selection biased that been mainly resulted from recruitment of cases from infertility centers. Moreover despite lack of normality assumption for TPOAb levels, they compared means for reporting significance. Furthermore the milder subjects may be spontaneously fertilized and not included in the study and this problem eliminates in a population-based study. Our study is in agreement with study conducted by Soltanghorae H et al.; they found no significant difference between median of TPOAb of infertile men/women and fertile ones (2.6 IU/ml vs 2.6 IU/ml in male, 2.8 IU/

| Table 2 | The Odds Ratio and 95% Confidence interval of TPOAb status and female infertility, abortion, thyroid dysfunction with controls |
|---------|---------------------------------------------------------------|
| TPO Ab  | Infertility | *OR (95%CI) | p-value | Abortion | *OR (95%CI) | p-value |
| Positive (≥35) | Yes 50 (17.9%) | 332 (18.2%) | 0.98 (0.7–1.4) | 0.721 | No 230 (82.1%) | 1496 (81.8%) | REF |
| Negative (<35) | Yes 92 (32.9%) | 585 (32.0%) | 1.04 (0.8–1.4) | 0.845 | No 188 (67.1%) | 1243 (68.0%) | REF |

* significant p-value < 0.05
* logistic regression was applied to obtain crude OR (95%CI)

| Table 3 | Results of crude and adjusted logistic regression analysis of infertility by thyroid function and TPOAb status |
|---------|---------------------------------------------------------------|
| Female | | Male | |
| Crude models | *OR of infertility (95%CI) | P_value | *OR of infertility (95%CI) | P_value |
| FT4 (ng/dl) | 0.997 (0.602–1.650) | 0.991 | 0.189 (0.056, 0.637) | * 0.007 |
| TSH (mU/L) | 1.015 (0.976–1.054) | 0.458 | 1.028 (1.001, 1.055) | * 0.042 |
| TPOAb (IU/ml) | 0.999 (0.998–1.000) | 0.222 | 1.00 (0.996, 1.003) | 0.833 |
| TPOAb Positive | 1.0 (0.8–1.35) | 0.953 | 0.7 (0.3, 1.5) | 0.392 |
| Negative (ref) | | | | |

Age-and-BMI-Adjusted models

| FT4 (ng/dl) | 1.003 (0.600–1.676) | 0.991 | 0.280 (0.081, 0.967) | * 0.044 |
| TSH (mU/L) | 1.012 (0.974–1.052) | 0.536 | 1.025 (0.998, 1.052) | 0.070 |
| TPOAb (IU/ml) | 0.999 (0.998–1.000) | 0.194 | 1.00 (0.996, 1.003) | 0.874 |
| TPOAb Positive | 0.97 (0.7, 1.35) | 0.888 | 0.7 (0.3, 1.6) | 0.416 |
| Negative (ref) | | | | |

Multi-Adjusted models

| FT4 (ng/dl) | 1.007 (0.596–1.702) | 0.978 | 0.265 (0.075, 0.940) | * 0.040 |
| TSH (mU/L) | 1.012 (0.973–1.052) | 0.552 | 1.026 (0.999, 1.053) | 0.061 |
| TPOAb (IU/ml) | 0.999 (0.998–1.000) | 0.196 | 1.00 (0.997, 1.003) | 0.915 |
| TPOAb Positive | 0.983 (0.694–1.393) | 0.924 | 0.778 (0.304, 1.992) | 0.610 |
| Negative (ref) | | | | |

*significant p-value < 0.05
*Adjusted by Age, education, BMI, Smoking, Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Fasting blood Sugar (FBS)
### Table 4
Results of crude and adjusted linear regression analysis for the time to pregnancy, number of abortions & parity by thyroid function and TPOAb status

| Exposure (time to pregnancy) | Coefficient (95%CI) | * P_value |
|-----------------------------|---------------------|-----------|
| **Crude models**            |                     |           |
| FT4 (ng/dl)                 | −0.890 (−4.168–2.388) | −0.594 |
| TSH (mU/L)                  | 0.086 (−0.167–0.340)  | 0.505    |
| TPOAb (IU/ml)               | −0.000 (−0.006–0.006) | 0.891    |
| TPOAb Positive              | 0.64 (−2.1, 3.4)      | 0.648    |
| (ref)                       |                     |           |

| **Adjusted model 1#**       |                     |           |
| FT4 (ng/dl)                 | −0.768 (−4.118–2.592) | 0.644    |
| TSH (mU/L)                  | 0.079 (−0.175–0.333)  | 0.543    |
| TPOAb (IU/ml)               | −0.000 (−0.006–0.006) | 0.958    |
| TPOAb Positive              | 0.56 (−2.1, 3.3)      | 0.688    |
| (ref)                       |                     |           |

| **Adjusted model 2##**      |                     |           |
| FT4 (ng/dl)                 | −0.759 (−4.109–2.592) | 0.657    |
| TSH (mU/L)                  | 0.087 (−0.168–0.343)  | 0.502    |
| TPOAb (IU/ml)               | −0.000 (−0.006–0.006) | 0.986    |
| TPOAb Positive              | 0.56 (−2.1, 3.3)      | 0.688    |
| (ref)                       |                     |           |

| Exposure number of Abortion | The coefficient (95%CI) | P_value |
|-----------------------------|-------------------------|---------|
| **Crude models**            |                         |         |
| FT4 (ng/dl)                 | −0.182 (−0.368–0.005)   | 0.057   |
| TSH (mU/L)                  | 0.00 (−0.014–0.015)     | 0.969   |
| TPOAb (IU/ml)               | 0.00 (0.00–0.00)        | 0.788   |
| TPOAb Positive              | 0.03 (−1.5, .20)        | 0.775   |
| (ref)                       |                         |         |

| **Adjusted model 1#**       |                         |         |
| FT4 (ng/dl)                 | −0.058 (−0.246–0.130)   | 0.544   |
| TSH (mU/L)                  | 0.005 (−0.010–0.019)    | 0.526   |
| TPOAb (IU/ml)               | 0.00 (0.00–0.00)        | 0.822   |
| TPOAb Positive              | 0.03 (−1.5, .20)        | 0.744   |
| (ref)                       |                         |         |

| **Adjusted model 2##**      |                         |         |
| FT4 (ng/dl)                 | −0.043 (−0.232–0.146)   | 0.657   |
| TSH (mU/L)                  | 0.004 (−0.010–0.018)    | 0.592   |
| TPOAb                       | 0.00 (0.00–0.00)        | 0.785   |
| TPOAb Positive              | 0.03 (−1.5, .20)        | 0.744   |
| (ref)                       |                         |         |

| **Exposures**               | Coefficient for Parity(95%CI) | P_value |
|-----------------------------|--------------------------------|---------|
| **Crude mode**              |                                |         |
| FT4 (ng/dl)                 | −0.634 (−0.863 – – 0.405)      | 0.000*  |
| TSH (mU/L)                  | −0.010 (−0.027–0.008)          | 0.291   |
| TPOAb (IU/ml)               | 0.00 (0.00–0.00)               | 0.891   |
| TPOAb Positive              | − 0.2 (−1.18, .14)            | 0.830   |
ml vs 2.6 IU/ml in female). Moreover they observed no association between thyroid autoimmunity and spontaneous abortion, similar to our results.

There are several studies investigating the prevalence of thyroid autoimmunity in women seeking infertility services. Marcos Abalovich et al. demonstrated no significant difference between TAI prevalence of infertile women with the control group (26.6% vs 14.5%) [23]. K. Poppe et al. conducted a study in 438 infertile women to investigate the prevalence of thyroid antibodies in infertile women with different causes included female or male cause and idiopathic. The thyroid test and thyroid autoimmunity association were evaluated in different groups of infertile females. The prevalence of infertility was 45, 38 and 17% in the female cause, male cause and idiopathic. TPOAb positivity was higher in all women of infertile couples but with no significant difference. In subgroup infertile women only in endometriosis TPOAb positivity showed significant difference compared with controls (18% vs 8%) [24].

In a study by Grassi G et al. in 149 infertile couples with the evaluation of the etiology of infertility and thyroid autoantibodies (Tg Ab, microsomal Ab), 20.1% had a detectable level of TgAb and/or M Ab and in euthyroid infertile women with thyroid autoantibodies, detected no difference either in age of subjects or duration of infertility [25].

There is a limited number of studies reported thyroid autoimmunity among male with infertility. Thyroid autoantibodies can be associated with sperm antibodies in infertile men [26, 27]. In a study by Harald Trummer et al. that been conducted among 305 infertile men; they reported no significant correlation between thyroid dysfunction and semen parameters, except for TPOAb positivity that was positively associated with pathozoospermia (6.7% vs 1.6%, \( P = .036 \)) and asthenozoospermia (7.2% vs 1.6%, \( P = .049 \)) [7]. However they have not reported the association of autoimmunity and thyroid dysfunction with male infertility despite having adequate sample size.

In the present study, we found a negative association between fT4 level in males (in both crude and adjusted models) with infertility. It has been shown that testosterone levels is decreased in hypothyroid men due to effect on hypothalamus-pituitary or alteration on prolactin secretion [28]. Indeed there is a significant decrease in male gonadal steroids suffered from hypothyroidism [29]. However there is no evidence to advice systematic screening for thyroid autoimmunity in infertile men without obvious clinical symptoms [30]. In the present study, we found a fall in fT4 level in both crude and adjusted models in males was associated with infertility although the TSH level showed no significant association that insufficient sample size could be the possible cause.

The current study has several limitations. We obtain data on infertility based on a self-reported questionnaire and observing their medical records if needed. Although there is a possibility of reducing the accuracy of self-reported questionnaire, however it may not mainly influence our results as it an acceptable method in the population-based study for infertility [31]; moreover history of infertility that much affects the couple life that they may never forget it and Second, we used a single measurement of thyroid test in the present study, while it should be noticed that thyroid status may be varied by the time. Even though Somwaru et al. reported that
subclinical hypothyroidism can be persistent in 56% at least for a 4-year follow-up [32]. Third, the number of men with confirmed male infertility was small and we had no adequate power for some comparison. Forth we have not assed other parameters for assessment of thyroid autoimmunity such as anti-thyroglobulin.

The main strength of our study is its methodology; as it is one of the few population-based studies about thyroid autoimmunity on infertility, especially male infertility.

All immunoassay tests in present study were performed in the same laboratory by skilled laboratory technicians. Furthermore, we excluded those participants using thyroid medication or those with overt hypothyroidism - hyperthyroidism to eliminate the effect of treatment on TFTs.

**Conclusion**

In conclusion, thyroid autoimmunity is not associated with infertility in both females and males. There is not sufficient data to recommend the infertile couple for assessment of thyroid autoimmunity or subclinical thyroid dysfunction. Further comprehensive population based studies with adequate sample size are highly suggested.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12902-021-00773-y.

**Additional file 1.** Reproductive questionnaire

**Acknowledgements**

None.

**Conflict of interests**

The authors declare no conflict of interests.

**Authors’ contributions**

Concept and design of the work has done by BB, FR, AA. Data acquisition, has done by BB, FR and RB. Data analysis, has done by RB. Data interpretation has done by BB, FR, AA, MT and FA. Drafting the work or revising it critically for important intellectual content has done by BB, FR and AA. Final approval of the version to be published, has done by all authors. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding**

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

**Availability of data and materials**

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the Regional Ethics Committee of Shahid Beheshti, Iran (Reg.number IR.SBMU.MSP.REC:1399:282). Written informed consent was obtained from all subjects.

**Consent for publication**

Not applicable.

**Competing interests**

None.

**Author details**

1Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, P.O. Box: 19395-4763, Tehran, IR, Iran. 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University, Tehran, Iran. 4Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

**Received:** 2 January 2021 **Accepted:** 19 May 2021

**Published online:** 26 May 2021

**References**

1. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev. 2003;24(5):694–717. https://doi.org/10.1210/er.2002-0030.

2. Poppe K, Velkeniers B, Glinier D. The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab. 2008;4(7):394–405. https://doi.org/10.1038/ncpenmed0846.

3. Twig G, Shina A, Amital H, Shoenfeld Y. Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun. 2012; 38(2–3):275–81. https://doi.org/10.1016/j.jaut.2011.11.014.

4. van den Boogaard E, Vissenberg R, Land JA, van Wely M, van der Post JA, Goddijn M, et al. Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review. Hum Reprod Update. 2011;17(5):605–19. https://doi.org/10.1093/humupd/dmr024.

5. Liu H, Shan Z, Li C, Mao J, Xie X, Wang W, et al. Maternal subclinical hypothyroidism, thyroid autoimmunity, and the risk of miscarriage: a prospective cohort study. Thyroid. 2014;24(11):1642–9. https://doi.org/10.1089/thy.2014.0029.

6. Kutteh WH, Yetman DL, Carr AC, Beck LA, Scott RT Jr. Increased prevalence of antithyroid antibodies identified in women with recurrent pregnancy loss but not in women undergoing assisted reproduction. Fertil Steril. 1999;71(5):843–8. https://doi.org/10.1016/S0015-0282(99)00091-6.

7. H T, Trummer H, Ramschak-Schwarzer S, Haas J, Habermann H, Pummer K, et al. Thyroid hormones and thyroid antibodies in infertile males. Fertil Steril. 2001;76(2):254–7. https://doi.org/10.1016/S0015-0282(01)01875-1.

8. Kucharčík M, Rozčí D. Thyroid Autoimmunity and Infertility: Kanner I, 2017.

9. Monteleone P, Pantri D, Faviana P, Carletti E, Casarosa E, Uccelli A, et al. Female infertility related to thyroid autoimmunity: the ovarian follicle hypothesis. Am J Reprod Immunol. 2011;66(2):108–14. https://doi.org/10.1111/j.1600-0897.2010.00961.x.

10. Geva E, Lessing JB, Lerner-Geva L, Azem F, Yovel I, Amit A. The presence of antithyroid antibodies in euthyroid patients with unexplained infertility and tubal obstruction. Am J Reprod Immunol. 1997;37(2):184–6. https://doi.org/10.1111/j.1600-0897.1997.tb00210.x.

11. Roussy RG, Kaidar BD, Price DE, Coulam CB. Laboratory evaluation of women experiencing reproductive failure. Am J Reprod Immunol. 1996; 35(4):415–20. https://doi.org/10.1111/j.1600-0897.1996.tb00503.x.

12. Heng BC, Huang W, Zhong X, Yin P, Tong GQ. Roles of antithyroid antibodies, Antithyroid antibodies and Antiperoxid antibodies in female reproductive health. Int Med J. 2015;2(1–2):21–31. https://doi.org/10.5901/000381900.

13. Feldthuesen AD, Pedersen PL, Larsen J, Toft Kristensen T, Ellervik C, Kvetny J. Impaired fertility associated with subclinical hypothyroidism and thyroid autoimmunity: the Danish general suburban population study. J Reproductive. 2015;2015:132718.

14. Kazemzadeh SA, Behboudi-Gharevani S, Hosseinpanah F, Khalili D, Azizi F. The prevalence and causes of primary infertility in Iran: a population-based study. Global J Health Sci. 2015;7(6):226–32. https://doi.org/10.5539/gjhs.v7n6p226.

15. Amouzegar A, Gharibzadeh S, Kazemian E, Mehan L, Tohidi M, Azizi F. The prevalence, incidence and natural course of positive Antithyroidoperoxidase
antibodies in a population-based study: Tehran thyroid study. "PloS One. 2017;12(1):e0169283. https://doi.org/10.1371/journal.pone.0169283.

16. Ramezani Tehrani F, Behboodi-Gandevani S, Rostami Dovom M, Farahmand M, Minooee S, Noroozzadeh M, et al. Reproductive assessment findings from 20 years of the Tehran lipid and glucose study. "Int J Endocrinol Metab. 2018;16(4 Suppl):e84786. https://doi.org/10.5812/ijem.84786.

17. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The international glossary on infertility and fertility care. 2017. Hum Reprod. 2017;32(9):1786–801. https://doi.org/10.1093/humrep/dex234.

18. Griebel CP, Halvorsen TB, Day AA. Management of spontaneous abortion. Am Fam Physician. 2005;72(7):1243–50.

19. Amouzegar A, Delshad H, Mehran L, Tohidi M, Khafaji F, Azizi F. Reference limit of thyrotropin (TSH) and free thyroxine (FT 4) in thyroperoxidase positive and negative subjects: a population based study. J Endocrinol Investig. 2013;36(11):950–4.

20. Habib ZV, Faghih N. Study of prevalence of anti-thyroid peroxidase (TPO) antibodies in EUTHYROID women with unexplained infertility referred to IVF CENTER in AFZALIPOUR hospital in 2013–2014. 2017.

21. Gupta J, Bansal CL, Ajmani SN, Ajmani AK. Role of thyroid dysfunction and thyroid autoimmunity in infertile women: study done in 450 bedded maternity hospital of Delhi, India. Int J Reproduct Contracept Obstet Gynecol. 2017;6(6):2598.

22. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab. 2007;92(12):4575–82. https://doi.org/10.1210/jc.2007-1499.

23. Abalovich M, Abalovich M, Mitelberg L, Allami C, Gutierrez S, Alcaraz C, et al. Subclinical hypothyroidism and thyroid autoimmunity in women with infertility. Gynecol Endocrinol. 2007;23(5):279–83. https://doi.org/10.1080/09513590701259542.

24. Poppe K, Glinser D. Thyroid autoimmunity and hypothyroidism before and during pregnancy. Hum Reprod Update. 2003;9(2):149–61. https://doi.org/10.1093/humupd/dmg012.

25. Grassi G, Balsamo A, Ansaldi C, Balbo A, Massobrio M, Benedetto C. Thyroid autoimmunity and infertility. Gynecol Endocrinol. 2001;15(5):389–96. https://doi.org/10.1080/09513590110093396.

26. Paschke R, Bertelsbeck DS, Tsalimalia K, Nieschlag E. Association of sperm antibodies with other autoantibodies in infertile men. Am J Reprod Immunol. 1994;32(2):88–94. https://doi.org/10.1111/j.1600-0897.1994.tb0198.x.

27. Baker HG, Clarke GN, McGowan MP, Koh SH, Cauchi MN. Increased frequency of autoantibodies in men with sperm antibodies. Fertil Steril. 1985;39(3):438–41. https://doi.org/10.1016/S0015-0282(16)48445-1.

28. Donnelly P, White C. Testicular dysfunction in men with primary hypothyroidism: reversal of hypogonadotropic hypogonadism with replacement thyroxine. Clin Endocrinol. 2000;52(2):197–201. https://doi.org/10.1046/j.1365-2265.2000.00918.x.

29. Kumar A, Shekhar S, Dhole B. Thyroid and male reproduction. Indian J Endocrinol Metab. 2014;18(1):23–31. https://doi.org/10.4103/2230-8210.126523.

30. Poppe K, Glinser D, Tournaye H, Maniewski U, Haentjens P, Velkeniers B. Is systematic screening for thyroid disorders indicated in subfertile men? Eur J Endocrinol. 2006;154(3):363–6. https://doi.org/10.1530/eje.1.02098.

31. Datta J, Palmer M, Tanton C, Gibson L, Jones K, Macdowall W, et al. Prevalence of infertility and help seeking among 15,000 women and men. Hum Reprod. 2016;31(3):2108–18. https://doi.org/10.1093/humrep/dew123.

32. Somwaru LL, Rarty CM, Arnold AM, Cappola AR. The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. J Clin Endocrinol Metab. 2012;97(6):1962–9. https://doi.org/10.1210/jc.2011-3047.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions